MedTrace Logo

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

NCT06586515 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 630

Last updated 2026-04-20

No results posted yet for this study

Summary

The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

Conditions

Interventions

DRUG

LY3962673

Administered orally.

DRUG

Cetuximab

Administered intravenously.

DRUG

Gemcitabine

Administered intravenously.

DRUG

nab-paclitaxel

Administered intravenously.

DRUG

Oxaliplatin

Administered intravenously.

DRUG

leucovorin

Administered intravenously.

DRUG

Irinotecan

Administered intravenously.

DRUG

5-fluorouracil

Administered intravenously.

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-12
Primary Completion
2029-03-31
Completion
2029-03-31
FDA Drug
Yes

Countries

  • United States
  • Canada
  • China
  • France
  • Germany
  • Ireland
  • Italy
  • Japan
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06586515 on ClinicalTrials.gov